The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua
A high-stakes court battle is currently being fought in the US, with the government accusing a big pharma company of patent infringement for the first time.
Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t
The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t
Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin